Dana-farber-cancer Institute Inc.

Sanofi

Pionyr Immunotherapeutics, Inc.

Michel Streuli

Paul J Anderson

Stuart F Schlossman

Leonard G Presta

Daniel J Tavares

Chonghui Zhang

Veronique Blanc

Fabienne Parker

Venkataraman Sriram

Claudia Fromond

Jiawen Han

Min Li

Xiao-Mai Zhou

Aritra Pal

Linda Liang

Sayantan Mitra

Xi Yang

Linnea Haeggblom

Vladislava Juric

Kara Mojica

Joshua Pollack

Nadine Jahchan

Andreas Beck

Carles Serra-Pages

Anne Debant

Véronique Blanc

Min Immunogen Inc Li

Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.

Anti-MARCO antibodies and uses thereof

Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.

Anti-TREM2 antibodies and related methods

Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.

EPHA2 receptor antagonist antibodies

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.

Methods of use for antibodies that specifically bind to the EphA2 receptor

The invention features transgenic non-human mammals containing a mutation in one or both alleles of the endogenous TIAR gene, and cell lines derived from some of these mammals. The mammals and cell lines of the invention can be employed to identify compounds useful in treating infertility, obesity, neurological disorders, and ovarian sex cord stromal tumors.

Trangenic mice with a disruption in the tiar gene

Nucleic acids encoding TRIO proteins, the TRIO proteins themselves, and active portions thereof as described. In addition, antibodies immunoreactive with TRIO proteins, and preparations of such compositions are provided. Diagnostic and therapeutic assays and reagents for detecting and treating disorders involving, for example, aberrant expression (or loss thereof) of the TRIO protein are described. Assays are provided for identifying agents that modulate the biological function of TRIO proteins.

Trio molecules and uses related thereto

A purified preparation of a polypeptide that is immunologically reactive with the monoclonal antibody produced by the hybridoma designated ATCC # HB 10319.

Proteins active in lymphocyte-mediated cytotoxicity

An isolated DNA that includes a sequence encoding a polypeptide with which the monoclonal antibody TIA-1 produced by the hybridoma designated ATCC#HB10319 is immunologically reactive; a vector or a cell containing such a DNA; and a method of using such a DNA to identify cytolytic lymphocytes.

DNAS encoding proteins active in lymphocyte-medicated cytotoxicity

DNA encoding a protein active in lymphocyte-mediated cytotoxicity

A 15 kd protein antigen is associated with cytoplasmic granules in cytolytic T lymphocytes and natural killer cells. Monoclonal antibodies immunologically reactive with the 15 kd protein and nucleic acid probes encoding polypeptides that are immunologically cross-reactive with the 15 kd protein can be used, e.g., to identify cytolytic lymphocytes in a sample. Cloned cDNA encoding the antigen can be used to produce the antigen.

Intracellular antigen found in subpopulation of CD8.sup.+ T lymphocytes

Growing community of inventors

Brookline, MA, United States of America

Michel Streuli